UPDATED: Hedge fund aims to oust Depomed board for ‘troubling record’

Eric Palmer If Depomed thought it was free to chart its own course after foiling a takeover by Horizon Pharma last year, it can think again. A hedge fund practiced in the art of board ...

UPDATED: Endo aims to lure Salix from Valeant with $175-per-share offer

Carly Helfand Last month, some industry watchers speculated that the low price Valeant agreed to pay for North Carolina's Salix could leave room for other bids. And now, one has ...

Hedge fund exec aims new legal weapon at Big Pharma’s ‘evergreened’ patents

Emily Wasserman As companies, regulators and advocacy groups lobby to bring certain branded products off-patent, a new voice is joining the chorus. U.S. hedge fund manager Kyle Bass, ...

France aims to save big bucks by subbing unapproved Avastin for eye drug Lucentis

Arlene Weintraub In June, the Italian government said it would pay for Roche's cancer drug Avastin to be used to treat a blinding eye disease, in place of the company's ...

U.S. access group aims to block Indian patent for Gilead’s hot hep C drug

Tracy Staton Gilead Sciences' new hepatitis C drug sofosbuvir won preliminary backing from European regulators on Friday, with marketing approval expected to follow soon. The FDA ...

Pfizer aims ambitious PCSK9 program at payers, skeptical regulators

Tracy Staton Tantalized by various megablockbuster projections for the PCSK9 field of cholesterol drugs, Pfizer has mapped out one of the most ambitious late-stage programs ...

Egalet scores up to $20M for next-gen pain drug as FDA aims to block abuse

Ryan McBride The company develops drug-delivery platforms that offer therapeutic release of pain medicines while making them difficult to abuse. With the new capital, the company plans ...

Bayer aims at hot cancer immunotherapy race with $540M R&D deal

John Carroll Shares of Israel's Compugen soared more than 60% this morning after the Israeli biotech signed on to a collaboration with Bayer to find new antibody-based cancer immunotherapies.  FierceBiotech ...

New Accenture service aims to enhance drug development and discovery

mia.burns By Mia Burns The global management consulting, technology services, and outsourcing company Accenture has launched a business service called  Accenture Accelerated R&D ...

Conatus Pharma aims for $69M IPO to fund liver-disease drug

Ryan McBride Conatus Pharmaceuticals has joined a long line of drug developers seeking to go public. The San Diego-based company, which has a lead drug candidate acquired from Pfizer, ...
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS